Oxford Biomedica Regulatory News (OXB)

Oxford Biomedica

Block Listing Application

Oxford, UK - 28 May 2021: Oxford Biomedica plc ("OXB" or "the Group") (LSE: OXB), announces that applications have been made to the Financial Conduct Authority and the London Stock Exchange for admission to (i) the Premium segment of the Official List and (ii) to trading on the London Stock Exchange for a block listing of 600,000 new ordinary shares of 50 pence each (the "New Ordinary Shares").

The New Ordinary Shares are being reserved under a block listing and will be issued from time to time pursuant to the following schemes:

· OXB Long Term Incentive Plan (LTIP) (200,000 New Ordinary Shares);

· OXB Employee Share Option Scheme (ESOS) (150,000 New Ordinary Shares);

· OXB Save As You Earn Option Scheme (SAYE) (150,000 New Ordinary Shares); and

· OXB Deferred Bonus Plan (DBP) Share Option Scheme (100,000 New Ordinary Shares).

It is expected that admission to the Official List and the London Stock Exchange of the New Ordinary Shares will become effective on 04 June 2021. The New Ordinary Shares will rank pari passu in all respects with the Group's existing ordinary shares in issue.

-Ends-

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a three year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 670 people. Further information is available at www.oxb.com